Constellation pharmaceuticals inc (CNST)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Dec'17
Assets
Current assets:
Cash and cash equivalents

190,464

334,332

78,977

55,043

52,447

114,592

128,475

88,540

16,404

Marketable securities

168,385

49,602

10,089

43,057

63,344

-

-

-

-

Prepaid expenses and other current assets

2,817

3,055

3,144

2,566

2,695

2,711

3,537

2,065

1,318

Total current assets

361,666

386,989

92,210

100,666

118,486

117,303

132,012

90,605

17,722

Property and equipment, net

867

971

1,149

1,176

1,312

1,210

825

885

1,121

Deferred offering costs

-

-

61

-

-

-

-

2,890

-

Restricted cash

425

425

425

425

425

425

425

242

242

Operating lease, right-of-use assets

10,103

10,745

11,372

11,986

4,700

-

-

-

-

Other assets

-

-

-

-

-

-

-

-

18

Total assets

373,061

399,130

105,217

114,253

124,923

118,938

133,262

94,622

19,103

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable

3,558

7,278

4,983

6,387

7,523

5,723

4,309

2,679

2,799

Accrued expenses and other current liabilities

12,980

12,915

10,389

8,607

6,628

8,937

6,212

6,129

4,229

Current portion of lease liabilities - operating lease

2,747

2,562

2,382

2,207

2,970

-

-

-

-

Current portion of long-term debt, net of discount

-

-

-

-

-

-

-

605

4,103

Total current liabilities

19,285

22,755

17,754

17,201

17,121

14,660

10,521

9,413

11,131

Long-term debt, net of current portion and discount

29,681

29,642

29,603

19,568

19,529

-

-

-

-

Operating lease liabilities, net of current portion

8,016

8,759

9,481

10,185

2,185

-

-

-

-

Preferred stock warrant liability

-

-

-

-

-

-

-

-

254

Preferred stock warrant liability

-

-

-

-

-

-

-

352

-

Deferred rent, net of current portion

-

-

-

-

-

118

176

235

317

Other long-term liabilities

553

390

227

115

13

2

2

3

6

Total liabilities

57,535

61,546

57,065

47,069

38,848

14,780

10,699

10,003

11,708

Commitments and contingencies (Note 8)

-

-

-

-

-

-

0

0

-

Convertible preferred stock (Series A, B, D, E, E-1 and F), $0.001 par value; no shares and 119,391,806 shares authorized at December 31, 2018 and 2017, respectively; no shares and 118,867,177 shares issued and outstanding at December 31, 2018 and 2017, respectively; aggregate liquidation preference of $0 and $178,762 at December 31, 2018 and 2017, respectively

-

-

-

-

-

-

-

272,834

173,228

Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding at March 31, 2020 and December 31, 2019, respectively

-

-

-

-

-

-

0

-

-

Common stock, $0.0001 par value; 200,000,000 shares authorized at March 31, 2020 and December 31, 2019, respectively; 41,822,064 and 41,719,039 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively;

4

4

3

3

3

3

3

0

-

Additional paid-in capital

660,443

656,973

343,327

341,200

339,326

337,992

336,453

9,740

8,079

Accumulated other comprehensive loss

-90

-6

1

11

9

-

-

-

-

Accumulated deficit

-344,831

-319,387

-295,179

-274,030

-253,263

-233,837

-213,893

-197,955

-173,912

Total stockholders' equity

315,526

337,584

48,152

67,184

86,075

104,158

122,563

-188,215

-165,833

Total liabilities and stockholders' equity

373,061

399,130

105,217

114,253

124,923

118,938

133,262

94,622

19,103